Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.
Please read the tutorial at this link. https://ebooknice.com/page/post?id=faq
We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.
For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.
EbookNice Team
Status:
Available0.0
0 reviewsSUMMARYMajor progress has been made in elucidating the molecular, cellular, and supracellular mechanisms underlying aging. This has spurred the birth of geroscience, which aims to identify actionable hallmarks of aging.Aging can be viewed as a process that is promoted by overactivation of gerogenes, i.e., genes and molecularpathways that favor biological aging, and alternatively slowed down by gerosuppressors, much as cancersare caused by the activation of oncogenes and prevented by tumor suppressors. Such gerogenes and gerosuppressors are often associated with age-related diseases in human population studies but also offer targets for modeling age-related diseases in animal models and treating or preventing such diseases in humans.Gerogenes and gerosuppressors interact with environmental, behavioral, and psychological risk factors todetermine the heterogeneous trajectory of biological aging and disease manifestation. New molecularprofiling technologies enable the characterization of gerogenic and gerosuppressive pathways, which serveas biomarkers of aging, hence inaugurating the era of precision geromedicine. It is anticipated that, pendingresults from randomized clinical trials and regulatory approval, gerotherapeutics will be tailored to each person based on their genetic profile, high-dimensional omics-based biomarkers of aging, clinical and digitalbiomarkers of aging, psychosocial profile, and past or present exposures.